Cargando…
The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer
BACKGROUND: The treatment of differentiated thyroid cancer (DTC) ends in full recovery in 80% of cases. However, in 20% of cases local recurrences or distant metastases are observed, for this reason DTC patients are under life-long follow-up. The most sensitive marker for recurrence is stimulated th...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521804/ https://www.ncbi.nlm.nih.gov/pubmed/26230494 http://dx.doi.org/10.1371/journal.pone.0133852 |
_version_ | 1782383859697975296 |
---|---|
author | Kowalska, Aldona Pałyga, Iwona Gąsior-Perczak, Danuta Walczyk, Agnieszka Trybek, Tomasz Słuszniak, Anna Mężyk, Ryszard Góźdź, Stanisław |
author_facet | Kowalska, Aldona Pałyga, Iwona Gąsior-Perczak, Danuta Walczyk, Agnieszka Trybek, Tomasz Słuszniak, Anna Mężyk, Ryszard Góźdź, Stanisław |
author_sort | Kowalska, Aldona |
collection | PubMed |
description | BACKGROUND: The treatment of differentiated thyroid cancer (DTC) ends in full recovery in 80% of cases. However, in 20% of cases local recurrences or distant metastases are observed, for this reason DTC patients are under life-long follow-up. The most sensitive marker for recurrence is stimulated thyroglobulin (Tg) which, together with neck ultrasound (US), enables correct diagnosis in nearly all cases of the active disease. For many years the only known stimulation was a 4–5 week withdrawal from the L-T4 therapy (THW). For the last couple of years stimulation with the use of recombinant human TSH (rhTSH) has been available. This method of stimulation may have a significant influence in obtaining the Tg level. However, it is important to determine the cut-off level for rhTSH-stimulated Tg (rhTSH/Tg). MATERIALS AND METHODS: This is a retrospective analysis of consecutive patients from one facility who have qualified over a period of two years for repeated radioiodine therapy (RIA). In our facility the ablation effectiveness evaluation is always carried out with the use of rhTSH, with the repeated therapy following THW. Such a procedure enables two Tg measurements in the same patient after both types of stimulation within 4–5 weeks. The obtained values were compared, cut-off levels in THW conditions were used (2.0 ng/ml for patients in remission and 10.0 ng/ml for patients with an active disease). In order to determine the cut-off level for rhTSH/Tg, regression analysis and ROC curves were used. RESULTS: In 63 patients the Tg measurement of both methods of stimulation were obtained. It was observed that there was a high correlation between rhTSH/Tg and THW/Tg. However, the rhTSH/Tg level was significantly lower than THW/ Tg. The rhTSH/ Tg cut-off levels which corresponded to the 2.0 ng/ml and 10.0 ng/ml limits for THW/Tg were calculated and the values were 0.6 ng/ml and 2.3 ng/ml respectively. CONCLUSIONS: The method of stimulation has a significant impact on the obtained Tg concentrations. The assumed THW/Tg cut off levels must not be transferred to rhTSH/Tg. |
format | Online Article Text |
id | pubmed-4521804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-45218042015-08-06 The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer Kowalska, Aldona Pałyga, Iwona Gąsior-Perczak, Danuta Walczyk, Agnieszka Trybek, Tomasz Słuszniak, Anna Mężyk, Ryszard Góźdź, Stanisław PLoS One Research Article BACKGROUND: The treatment of differentiated thyroid cancer (DTC) ends in full recovery in 80% of cases. However, in 20% of cases local recurrences or distant metastases are observed, for this reason DTC patients are under life-long follow-up. The most sensitive marker for recurrence is stimulated thyroglobulin (Tg) which, together with neck ultrasound (US), enables correct diagnosis in nearly all cases of the active disease. For many years the only known stimulation was a 4–5 week withdrawal from the L-T4 therapy (THW). For the last couple of years stimulation with the use of recombinant human TSH (rhTSH) has been available. This method of stimulation may have a significant influence in obtaining the Tg level. However, it is important to determine the cut-off level for rhTSH-stimulated Tg (rhTSH/Tg). MATERIALS AND METHODS: This is a retrospective analysis of consecutive patients from one facility who have qualified over a period of two years for repeated radioiodine therapy (RIA). In our facility the ablation effectiveness evaluation is always carried out with the use of rhTSH, with the repeated therapy following THW. Such a procedure enables two Tg measurements in the same patient after both types of stimulation within 4–5 weeks. The obtained values were compared, cut-off levels in THW conditions were used (2.0 ng/ml for patients in remission and 10.0 ng/ml for patients with an active disease). In order to determine the cut-off level for rhTSH/Tg, regression analysis and ROC curves were used. RESULTS: In 63 patients the Tg measurement of both methods of stimulation were obtained. It was observed that there was a high correlation between rhTSH/Tg and THW/Tg. However, the rhTSH/Tg level was significantly lower than THW/ Tg. The rhTSH/ Tg cut-off levels which corresponded to the 2.0 ng/ml and 10.0 ng/ml limits for THW/Tg were calculated and the values were 0.6 ng/ml and 2.3 ng/ml respectively. CONCLUSIONS: The method of stimulation has a significant impact on the obtained Tg concentrations. The assumed THW/Tg cut off levels must not be transferred to rhTSH/Tg. Public Library of Science 2015-07-31 /pmc/articles/PMC4521804/ /pubmed/26230494 http://dx.doi.org/10.1371/journal.pone.0133852 Text en © 2015 Kowalska et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Kowalska, Aldona Pałyga, Iwona Gąsior-Perczak, Danuta Walczyk, Agnieszka Trybek, Tomasz Słuszniak, Anna Mężyk, Ryszard Góźdź, Stanisław The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer |
title | The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer |
title_full | The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer |
title_fullStr | The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer |
title_full_unstemmed | The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer |
title_short | The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer |
title_sort | cut-off level of recombinant human tsh-stimulated thyroglobulin in the follow-up of patients with differentiated thyroid cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521804/ https://www.ncbi.nlm.nih.gov/pubmed/26230494 http://dx.doi.org/10.1371/journal.pone.0133852 |
work_keys_str_mv | AT kowalskaaldona thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT pałygaiwona thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT gasiorperczakdanuta thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT walczykagnieszka thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT trybektomasz thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT słuszniakanna thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT mezykryszard thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT gozdzstanisław thecutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT kowalskaaldona cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT pałygaiwona cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT gasiorperczakdanuta cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT walczykagnieszka cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT trybektomasz cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT słuszniakanna cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT mezykryszard cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer AT gozdzstanisław cutofflevelofrecombinanthumantshstimulatedthyroglobulininthefollowupofpatientswithdifferentiatedthyroidcancer |